A diagnostic test that uses an indigenously developed CRISPR technology to detect the genomic sequence of the SARS-CoV-2 virus is set to hit the domestic market.

The Tata CRISPR test, powered by CSIR-IGIB FELUDA, received the Drug Controller General of India’s approval for commercial launch, as per the Indian Council of Medical Research guidelines, a note from the Tata Group said, adding that the test met the quality benchmarks with 96 percent sensitivity and 98 percent specificity for detecting the novel coronavirus.

CRISPR is a genome editing technology to diagnose diseases. But the Tata CRISPR test is touted to be the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19, the company said. And it had accuracy levels of the traditional RT-PCR (Real Time- Polymerase Chain Reaction) tests, with quicker turnaround time, less expensive equipment, and greater ease of use, it

Read More

The Tata CRISPR test, powered by CSIR-IGIB FELUDA, has received regulatory approvals from the Drug Controller General of India (DCGI) for commercial launch, meeting the quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting the novel coronavirus, a note from the Tata Group said.

This test uses an indigenously developed CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, it added.

“The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19. This marks a significant achievement for the Indian scientific community, moving from R&D (research and development) to a high-accuracy, scalable and reliable test in less than 100 days,” the note said, adding that the Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use.

Besides, it

Read More